Cat. No. | Product name | CAS No. |
DC47622 |
Cyclizine
Featured
Cyclizine is a piperazine first-generation antagonist of histamine 1 receptor. |
82-92-8 |
DC47678 |
M435-1279
Featured
M435-1279 is a UBE2T inhibitor. M435-1279 acts inhibit the Wnt/β-catenin signaling pathway hyperactivation through blocking UBE2T-mediated degradation of RACK1. |
1359431-16-5 |
DC47683 |
Mesdopetam hemitartrate
Featured
Mesdopetam (IRL790) hemitartrate is a dopamine D3 receptor antagonist (Ki=90 nM; IC50=9.8 μM for human recombinant D3 receptor) with psychomotor stabilizing properties. Mesdopetam hemitartrate is used for the research of motor and psychiatric complications in Parkinson disease. |
2562346-14-7 |
DC47703 |
BPR1R024
Featured
BPR1R024 is an orally active and selective CSF1R inhibitor with IC50 of 0.53 nM. BPR1R024 specifically inhibits protumor M2-like macrophage survival with a minimal effect on antitumor M1-like macrophage growth. |
2503015-75-4 |
DC47717 |
TAK-020
Featured
TAK-020 is a covalent Btk inhibitor, which becomes the clinical candidate. |
1627603-21-7 |
DC47718 |
AS-1763
Featured
AS-1763 is an orally available, potent, and selective BTK inhibitor and shows excellent potency against both wild/C481S mutant BTKs with IC50 of 0.85 nM/0.99 nM. |
2227211-00-7 |
DC47721 |
JNJ-67569762
Featured
JNJ-67569762 is a tetrahydropyridine-based BACE1 inhibitor targeting the S3 pocket with IC50 of 2.7 nM and shows 71-fold selectivity over BACE2. |
2380313-26-6 |
DC47754 |
Disitamab vedotin
Featured
Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent monomethyl auristatin E. Disitamab vedotin enhances antitumor immunity. |
2136633-23-1 |
DC47768 |
BMS-963272
Featured
BMS-963272 is a potent, selective MGAT2 inhibitor with IC50 of 7.1 nM/18 nM (hMGAT2/mMGAT2) and shows excellent efficacy, safety, and tolerability profile. |
1441057-15-3 |
DC47779 |
LysoTracker Red
Featured
LysoTracker Red (LysoTracker Red DND-99) is a paraformaldehyde fixable probe that concentrates into acidic compartments of cells and tissues. LysoTracker Red is an indicator of cell death in a manner similar to other standard assays (Annexin, terminal dUTP nick end labeling, Nile blue sulfate, neutral red, and acridine orange). LysoTracker Red is a marker for late endosomes and lysosomes. |
231946-72-8 |
DC47813 |
OG 488, acid
Featured
OG 488, acid, a fluorescent pH indicator, has many applications in biochemistry and neurosciences. |
195136-52-8 |
DC47823 |
Lepidiline A
Featured
Lepidiline A shows cytotoxic activity against HL-60 cells with an IC50 of 32.3 μM. |
596093-98-0 |
DC47847 |
Lepidiline C
Featured
Lepidiline C shows cytotoxic activity against HL-60 cells with an IC50 of 27.7 μM. |
2750933-59-4 |
DC47396 |
Abaloparatide (BA058)
Featured
Abaloparatide (BA058, BIM-44058, ITM-058) is a novel 34-amino acid peptide selected to be a potent and selective activator of the parathyroid hormone receptor (PTH1R) signaling pathway with an IC50 of 0.117 nM in SOST analysis. |
247062-33-5 |
DC58041 |
BMS-986176
Featured
AAK1-IN-1(BMS-986176) is a chemical probe for AAK1 and BIKE that potently targets the ATP-binding site (AAK1 Ki = 9.1 nM; BIKE Ki = 17 nM). Regarding kinase selectivity, only three kinases were observed to bind SGC-AAK1-1 within 30-fold of the KD of AAK1 in a KINOMEscan assay (DiscoverX) at 1 μM followed by KD determinations: RIOK1 (KD = 72 nM), RIOK3 (KD = 290 nM), and PIP5K1C (KD = 260 nM). In a live cell NanoBRET assay (Promega) SGC-AAK1-1 has potency for ectopically expressed full-length AAK1- and BIKE-Nluc fusion proteins (AAK1 IC50 = 230 nM; BIKE IC50 = 1.5 μM). |
1815613-42-3 |
DC58042 |
MRTX-282
Featured
MRTX-282 is a novel KRas G12D inhibitor. |
2621929-00-6 |
DC58046 |
C12-200
Featured
C12-200 is a cationic lipid for Lipid NanoParticles as delivery systems for enabling the therapeutic potential of siRNA, mRNA or CRISPR as they exhibit remarkable in vivo potencies at low doses.C12-200 is a common positive control ionizable lipid for exploring new ionizable lipids. C12-200 is an ionizable lipid with five tails. The tri-palmitoyl-Sglyceryl cysteine linked to the pentapeptide (Pam3)-modified C12-200 iLNPs was developed to deliver tumor antigen mRNA for enhancing the mRNA-mediated cancer immunotherapy. The results of the therapeutic evaluation showed that Pam3- modified C12-200 iLNPs could almost inhibit tumor growth in tumor-bearing mice. To improve delivery efficiency, the formulation was optimized to replace the phospholipids from DSPC to DOPE, and the result showed that optimized formulation induced EPO protein expression was seven times that of the initial formulation,[35] and the formulation has been used in the study for mRNA-mediated human α-galactosidase protein replacement therapy in mice and nonhuman primates. |
1220890-25-4 |
DC58047 |
DSPE-PEG 2000
Featured
PEG2000-DSPE is used for creating micelles that are able to carry drugs with low solubility. |
892144-24-0 |
DC60184 |
AZ194
Featured
AZ-194 is a first-in-class, orally active inhibitor of CRMP2-Ubc9 interaction and inhibitor of NaV1.7 (IC50=1.2 μM). AZ194 blocks SUMOylation of CRMP2 to selectively reduce the amount of surface-expressed NaV1.7. Antinociceptive effects[1]. |
2241651-99-8 |
DC60185 |
Giredestrant (tartrate)
Featured
Giredestrant, also known as GDC-9545 and RG6171, is a SERD. GDC-9545 is an orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, SERD GDC-9545 specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. |
2407529-33-1 |
DC60186 |
Difelikefalin HCl
Featured
Difelikefalin is a κ-opioid receptor (KOR) agonist. It activates KOR in HEK293 cells expressing the human receptor (EC50 = 0.16 nM in a transactivation assay) and inhibits forskolin-induced cAMP production in R1.G1 mouse thyoma cells (EC50 = 0.048 nM). Difelikefalin is selective for KOR over the μ-opioid receptor. |
2711717-77-8 |
DC60187 |
SWN41522
Featured
SWN41522, also known as DUPA and FN11, is a potent Urea-Based Inhibitor of Glutamate Carboxypeptidase II (NAALADase). In vivo antitumor tests using U-87 glioblastoma xenograft showed that FN11 reduced tumor vol. to a value of ∼0.4-0.6 (at 10 or 100 μM) after 4 days treatment, and ∼ 1.0 (at both dosages) after 7 days treatment. The antiangiogenesis activity of FN11 was examd. with similarly grown tumors, and revealed a preponderance of avascular and low vascular areas in tumors treated with FN11 at 100 μM. It was first reported in patent WO 2000064911 and Journal of Medicinal Chemistry (2001), 44(3), 298-301. |
302941-52-2 |